CHICAGO HIGHLIGHTS 2024 – LUNG ROUNDTABLE DISCUSSION: LAURA
OR
Chair
Dr. Barb Melosky
Panelists
Dr. Rosalyn Juergens
Dr. Peter Ellis
This program has been made possible through unrestricted support from Pfizer
Studies/trials discussed:
- Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
